Fam-trastuzumab deruxtecan-nxk (Enhertu) is a HER2-directed antibody and topoisomerase inhibitor conjugate that is designed to bind to the cancer cells expressing HER2 and then deliver the chemotherapy payload into the cells. It belongs to the class of antibody-drug conjugates or ADCs.
The drug is indicated for the treatment of patients with HER2-positive breast cancer, non-small cell lung cancer, gastric or gastroesophageal junction adenocarcinoma and solid tumors without alternative treatment options.